A phase 3 study of Amylyx Pharmaceuticals’ approved therapy for amyotrophic lateral sclerosis, Relyvrio, failed to find significant efficacy results. By mid-June, the drugmaker might withdraw the drug.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
